Senores Pharmaceuticals Limited — Investor Meet, 22-12-2025: Analysts/Institutional Investor Meet/Con. Call Updates

Senores Pharmaceuticals' Business Update Call detailed the acquisition of Apnar Pharma for Rs. 91 crore, including Rs. 76 crore in debt, to expand its regulated market footprint. This adds a USFDA, UK MHRA, and Health Canada-approved facility in Gujarat and five approved ANDAs. The plant, largely unutilized, is projected to contribute Rs. 100 crore-Rs. 120 crore revenue in FY27 with 30%+ EBITDA, scaling to Rs. 250 crore by FY28. This strategic move enables cost rationalization by shifting some US production to India, freeing up US capacity for higher-margin opportunities. Management views this as a "value buy" to enhance scalability and operational efficiency.